Drug
F17464
F17464: highest development phase Phase 2, developed by Pierre Fabre. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Pierre Fabre
Trials
| Drug | Phase | Indication |
|---|---|---|
| F17464 NCT02151656 | Phase 2 | Schizophrenia |
Latest
No recent events.
Follow F17464 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.